Logo image of RNA

AVIDITY BIOSCIENCES INC (RNA) Stock Fundamental Analysis

NASDAQ:RNA - Nasdaq - US05370A1088 - Common Stock - Currency: USD

29.32  -0.04 (-0.14%)

After market: 28.89 -0.43 (-1.47%)

Fundamental Rating

4

Taking everything into account, RNA scores 4 out of 10 in our fundamental rating. RNA was compared to 557 industry peers in the Biotechnology industry. RNA has a great financial health rating, but its profitability evaluates not so good. RNA is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

RNA had negative earnings in the past year.
In the past year RNA has reported a negative cash flow from operations.
In the past 5 years RNA always reported negative net income.
RNA had a negative operating cash flow in each of the past 5 years.
RNA Yearly Net Income VS EBIT VS OCF VS FCFRNA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M

1.2 Ratios

With a decent Return On Assets value of -25.31%, RNA is doing good in the industry, outperforming 72.53% of the companies in the same industry.
RNA has a Return On Equity of -27.79%. This is in the better half of the industry: RNA outperforms 79.89% of its industry peers.
Industry RankSector Rank
ROA -25.31%
ROE -27.79%
ROIC N/A
ROA(3y)-27.2%
ROA(5y)-24.5%
ROE(3y)-31.7%
ROE(5y)-28.1%
ROIC(3y)N/A
ROIC(5y)N/A
RNA Yearly ROA, ROE, ROICRNA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 500 1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for RNA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RNA Yearly Profit, Operating, Gross MarginsRNA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K

More info and screens

8

2. Health

2.1 Basic Checks

RNA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for RNA has been increased compared to 1 year ago.
RNA has more shares outstanding than it did 5 years ago.
RNA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
RNA Yearly Shares OutstandingRNA Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
RNA Yearly Total Debt VS Total AssetsRNA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

An Altman-Z score of 15.44 indicates that RNA is not in any danger for bankruptcy at the moment.
RNA has a better Altman-Z score (15.44) than 91.38% of its industry peers.
There is no outstanding debt for RNA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 15.44
ROIC/WACCN/A
WACC9.03%
RNA Yearly LT Debt VS Equity VS FCFRNA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

2.3 Liquidity

RNA has a Current Ratio of 16.91. This indicates that RNA is financially healthy and has no problem in meeting its short term obligations.
RNA has a better Current ratio (16.91) than 90.13% of its industry peers.
A Quick Ratio of 16.91 indicates that RNA has no problem at all paying its short term obligations.
RNA has a better Quick ratio (16.91) than 90.31% of its industry peers.
Industry RankSector Rank
Current Ratio 16.91
Quick Ratio 16.91
RNA Yearly Current Assets VS Current LiabilitesRNA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

6

3. Growth

3.1 Past

The earnings per share for RNA have decreased by -1.69% in the last year.
The Revenue for RNA has decreased by -17.92% in the past year. This is quite bad
RNA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 36.26% yearly.
EPS 1Y (TTM)-1.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.92%
Revenue 1Y (TTM)-17.92%
Revenue growth 3Y5.31%
Revenue growth 5Y36.26%
Sales Q2Q%-55.6%

3.2 Future

The Earnings Per Share is expected to grow by 23.73% on average over the next years. This is a very strong growth
RNA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 167.24% yearly.
EPS Next Y-41.57%
EPS Next 2Y-26.26%
EPS Next 3Y-2.67%
EPS Next 5Y23.73%
Revenue Next Year-29.4%
Revenue Next 2Y34.2%
Revenue Next 3Y237.44%
Revenue Next 5Y167.24%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
RNA Yearly Revenue VS EstimatesRNA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B 2B 2.5B
RNA Yearly EPS VS EstimatesRNA Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RNA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RNA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RNA Price Earnings VS Forward Price EarningsRNA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RNA Per share dataRNA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

RNA's earnings are expected to decrease with -2.67% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-26.26%
EPS Next 3Y-2.67%

More info and screens

0

5. Dividend

5.1 Amount

RNA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AVIDITY BIOSCIENCES INC

NASDAQ:RNA (6/18/2025, 8:25:27 PM)

After market: 28.89 -0.43 (-1.47%)

29.32

-0.04 (-0.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-07 2025-08-07/amc
Inst Owners110.49%
Inst Owner Change4.81%
Ins Owners0.97%
Ins Owner Change4.98%
Market Cap3.53B
Analysts83.33
Price Target68.12 (132.33%)
Short Float %14.45%
Short Ratio10.73
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.26%
Min EPS beat(2)-0.04%
Max EPS beat(2)0.55%
EPS beat(4)3
Avg EPS beat(4)7.18%
Min EPS beat(4)-0.04%
Max EPS beat(4)18.66%
EPS beat(8)5
Avg EPS beat(8)4.5%
EPS beat(12)8
Avg EPS beat(12)3.62%
EPS beat(16)11
Avg EPS beat(16)2.65%
Revenue beat(2)1
Avg Revenue beat(2)37.51%
Min Revenue beat(2)-18.03%
Max Revenue beat(2)93.05%
Revenue beat(4)1
Avg Revenue beat(4)1.5%
Min Revenue beat(4)-45.8%
Max Revenue beat(4)93.05%
Revenue beat(8)4
Avg Revenue beat(8)2.37%
Revenue beat(12)8
Avg Revenue beat(12)4.47%
Revenue beat(16)10
Avg Revenue beat(16)4.1%
PT rev (1m)-0.09%
PT rev (3m)-0.86%
EPS NQ rev (1m)-0.05%
EPS NQ rev (3m)-2.01%
EPS NY rev (1m)0%
EPS NY rev (3m)-22.62%
Revenue NQ rev (1m)-5.98%
Revenue NQ rev (3m)-17.44%
Revenue NY rev (1m)1.46%
Revenue NY rev (3m)-6.29%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 395.9
P/FCF N/A
P/OCF N/A
P/B 2.66
P/tB 2.66
EV/EBITDA N/A
EPS(TTM)-3
EYN/A
EPS(NY)-4.61
Fwd EYN/A
FCF(TTM)-3.03
FCFYN/A
OCF(TTM)-2.95
OCFYN/A
SpS0.07
BVpS11.02
TBVpS11.02
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -25.31%
ROE -27.79%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-27.2%
ROA(5y)-24.5%
ROE(3y)-31.7%
ROE(5y)-28.1%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 339.18%
Cap/Sales 110.94%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 16.91
Quick Ratio 16.91
Altman-Z 15.44
F-Score3
WACC9.03%
ROIC/WACCN/A
Cap/Depr(3y)219.55%
Cap/Depr(5y)307.52%
Cap/Sales(3y)46.55%
Cap/Sales(5y)39.16%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.92%
EPS Next Y-41.57%
EPS Next 2Y-26.26%
EPS Next 3Y-2.67%
EPS Next 5Y23.73%
Revenue 1Y (TTM)-17.92%
Revenue growth 3Y5.31%
Revenue growth 5Y36.26%
Sales Q2Q%-55.6%
Revenue Next Year-29.4%
Revenue Next 2Y34.2%
Revenue Next 3Y237.44%
Revenue Next 5Y167.24%
EBIT growth 1Y-69.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-57.8%
EBIT Next 3Y6.58%
EBIT Next 5YN/A
FCF growth 1Y-128.91%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-128.25%
OCF growth 3YN/A
OCF growth 5YN/A